Top Markets
#1 Black Phoenix Black Phoenix +860.56%
#2 QuantixAI QuantixAI +102.43%
#3 Nesa Nesa +39.29%
#4 MetaDAO MetaDAO +26.15%
#5 Pons Pons +23.30%
#6 LayerZero LayerZero +20.52%
#7 Bedrock Bedrock +19.99%
#8 Ontology Gas Ontology Gas +15.42%
#9 DOG•GO•TO•THE•MOON (Runes) DOG•GO•TO•THE•MOON (Runes) +15.08%
#10 Prom Prom +14.96%
Coin of the day
Black Phoenix Black Phoenix
Instellingen
Taal
DUTCH
Valuta
USD
Thema
Immunovant, Inc. Immunovant, Inc.

Immunovant, Inc.

IMVT
Rang in aandelen #2339
Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase,... Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in certain autoimmune diseases. Batoclimab is currently undergoing Phase IIa clinical evaluations for treating both myasthenia gravis and thyroid eye disease. Additionally, it has commenced Phase II clinical studies for patients suffering from warm autoimmune hemolytic anemia. Established in 2018, Immunovant operates from its headquarters in New York, New York, functioning as a subsidiary under the umbrella of Roivant Sciences Ltd.
Aandeelprijs
$43.48
Marktkapitalisatie
$8.97B
Verandering (1 dag)
0.37%
Verandering (1 jaar)
192.01%
Land
US
Handel Immunovant, Inc. (IMVT)

Categorie

Healthcare
Winst voor Immunovant, Inc. (IMVT)
Winst in 2026 TTM: 0
Volgens de meest recente financiële verslagen van Immunovant, Inc. bedraagt de huidige winst van het bedrijf 0. In 2026 behaalde het bedrijf een winst van 0, gelijk aan de winst van 2026, die 0 bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van Immunovant, Inc. van 2026 tot 2026
Winst aan het einde van elk jaar
Jaar Winst Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
Winst van vergelijkbare bedrijven of concurrenten
Bedrijf Winst Winstverschil Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH